Seeking Alpha

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) ...
Healio

Eylea HD

Aflibercept is used to treat certain serious eye conditions (such as macular edema/degeneration, diabetic retinopathy, retinopathy of prematurity). This medication can help preserve vision and prevent ...

Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea

By Kamal Choudhury Feb 17 (Reuters) - Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but its modest advantage and higher rates of certain ...
Seeking Alpha

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...
Fierce Pharma

Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...